featured
No Clinical Benefit Gained by Adding Onartuzumab in Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized, Phase 2, Placebo-Controlled Trial of Onartuzumab and/or Bevacizumab in Combination With Weekly Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer
Ann. Oncol 2015 Sep 01;26(9)1904-1910, V Diéras, M Campone, DA Yardley, G Romieu, V Valero, SJ Isakoff, H Koeppen, TR Wilson, Y Xiao, DS Shames, S Mocci, M Chen, P SchmidFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.